Cargando…
Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management
We evaluated for the first time, to our knowledge, adverse health outcomes (AHOs) among US testicular cancer survivors (TCS) given chemotherapy (n = 381) vs surgery-only patients (n = 98) managed at a single institution, accounting for non-treatment-related risk factors to delineate chemotherapy’s i...
Autores principales: | Agrawal, Vaibhav, Dinh, Paul C, Fung, Chunkit, Monahan, Patrick O, Althouse, Sandra K, Norton, Kelli, Cary, Clint, Einhorn, Lawrence, Fossa, Sophie D, Adra, Nabil, Travis, Lois B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065712/ https://www.ncbi.nlm.nih.gov/pubmed/32190815 http://dx.doi.org/10.1093/jncics/pkz079 |
Ejemplares similares
-
Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors
por: Fung, Chunkit, et al.
Publicado: (2018) -
Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors
por: Kerns, Sarah L, et al.
Publicado: (2020) -
Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24 900 Survivors
por: Milano, Michael T, et al.
Publicado: (2020) -
Salvage therapy for relapsed testicular cancer
por: Adra, Nabil, et al.
Publicado: (2017) -
Salvage therapy for relapsed testicular cancer
por: Adra, Nabil, et al.
Publicado: (2017)